The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
New developments for antibody-drug conjugate-based therapeutic approaches
Open accessAbstract
The clinical success of Adcetris(®) (brentuximab vedotin) and Kadcyla(®) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Physiological Parameters in Laboratory Animals and Humans
Davies, B., & Morris, T. (1993) · Pharmaceutical Research · doi:10.1023/a:1018943613122 · Cited by 2,926
Microtubule-binding agents: a dynamic field of cancer therapeutics
Dumontet, C., & Jordan, M. A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3253 · Cited by 1,718
Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
Lewis Phillips, G. D., Li, G., Dugger, D. L., Crocker, L. M., Parsons, K. L., Mai, E., Blättler, W. A., Lambert, J. M., Chari, R. V. J., Lutz, R. J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1776 · Cited by 1,676
Self-citationBrentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Younes, A., Bartlett, N. L., Leonard, J. P., Kennedy, D. A., Lynch, C. M., Sievers, E. L., & Forero-Torres, A. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002965 · Cited by 1,368
multifunctional enzymes in cancer
Mohamed, M. M., & Sloane, B. F. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1949 · Cited by 1,265
Francisco, J. A., Cerveny, C. G., Meyer, D. L., Mixan, B. J., Klussman, K., Chace, D. F., Rejniak, S. X., Gordon, K. A., DeBlanc, R., Toki, B. E., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0039 · Cited by 931
Bracci, L., Schiavoni, G., Sistigu, A., & Belardelli, F. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.67 · Cited by 928
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Ewer, M. S., Vooletich, M. T., Durand, J.-B., Woods, M. L., Davis, J. R., Valero, V., & Lenihan, D. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.13.300 · Cited by 726
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Press, M. F., Cordon‐Cardo, C., & Slamon, D. J. (1990) · PubMed · Cited by 638
Saunders, L. R., Bankovich, A. J., Anderson, W. C., Aujay, M. A., Bheddah, S., Black, K., Desai, R., Escarpe, P. A., Hampl, J., Laysang, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9459 · Cited by 600
Krop, I. E., Beeram, M., Modi, S., Jones, S. F., Holden, S. N., Yu, W., Girish, S., Tibbitts, J., Yi, J.-H., Sliwkowski, M. X., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.2071 · Cited by 595
Junttila, T. T., Li, G., Parsons, K., Phillips, G. L., & Sliwkowski, M. X. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1090-x · Cited by 541
Doronina, S. O., Mendelsohn, B. A., Bovee, T. D., Cerveny, C. G., Alley, S. C., Meyer, D. L., Oflazoglu, E., Toki, B. E., Sanderson, R. J., Zabinski, R. F., et al. (2006) · Bioconjugate Chemistry · doi:10.1021/bc0502917 · Cited by 515
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Tai, Y.-T., Mayes, P. A., Acharya, C., Zhong, M. Y., Cea, M., Cagnetta, A., Craigen, J., Yates, J., Gliddon, L., Fieles, W., et al. (2014) · Blood · doi:10.1182/blood-2013-10-535088 · Cited by 484
Kung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Müller, P., Kreuzaler, M., Khan, T., Thommen, D. S., Martin, K., Glatz, K., Savic, S., Harbeck, N., Nitz, U., Gluz, O., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac4925 · Cited by 349
Starodub, A. N., Ocean, A. J., Shah, M. A., Guarino, M. J., Picozzi, V. J., Vahdat, L. T., Thomas, S. S., Govindan, S. V., Maliakal, P. P., Wegener, W. A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3321 · Cited by 340
Advani, A., Coiffier, B., Czuczman, M. S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.1900 · Cited by 336
Palanca-Wessels, M. C. A., Czuczman, M., Salles, G., Assouline, S., Sehn, L. H., Flinn, I., Patel, M. R., Sangha, R., Hagenbeek, A., Advani, R., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70128-2 · Cited by 336
Tijink, B. M., Buter, J., de Bree, R., Giaccone, G., Lang, M. S., Staab, A., Leemans, C. R., & van Dongen, G. A. M. S. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0910 · Cited by 315
Immunoconjugates containing novel maytansinoids: promising anticancer drugs.
CHARI, R. V. J., Martell, B., Gross, J. L., Cook, S., Shah, S. A., Blättler, W. A., McKenzie, S. J., & Goldmacher, V. S. (1992) · PubMed · Cited by 266
Polson, A. G., Calemine-Fenaux, J., Chan, P., Chang, W., Christensen, E., Clark, S., de Sauvage, F. J., Eaton, D., Elkins, K., Elliott, J. M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2250 · Cited by 252
Jeffrey, S. C., Burke, P. J., Lyon, R. P., Meyer, D. W., Sussman, D., Anderson, M., Hunter, J. H., Leiske, C. I., Miyamoto, J. B., Nicholas, N. D., et al. (2013) · Bioconjugate Chemistry · doi:10.1021/bc400217g · Cited by 245
Breij, E. C. W., de Goeij, B. E. C. G., Verploegen, S., Schuurhuis, D. H., Amirkhosravi, A., Francis, J., Miller, V. B., Houtkamp, M., Bleeker, W. K., Satijn, D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2440 · Cited by 227
Self-citationElgersma, R. C., Coumans, R. G. E., Huijbregts, T., Menge, W. M. P. B., Joosten, J. A. F., Spijker, H. J., de Groot, F. M. H., van der Lee, M. M. C., Ubink, R., van den Dobbelsteen, D. J., et al. (2015) · Molecular Pharmaceutics · doi:10.1021/mp500781a · Cited by 221
Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)
Uppal, H., Doudement, E., Mahapatra, K., Darbonne, W. C., Bumbaca, D., Shen, B.-Q., Du, X., Saad, O., Bowles, K., Olsen, S., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2093 · Cited by 218
Argu¨eso, P., Spurr-Michaud, S., Russo, C. L., Tisdale, A., & Gipson, I. K. (2003) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.02-0862 · Cited by 212
Müller, P., Martin, K., Theurich, S., Schreiner, J., Savic, S., Terszowski, G., Lardinois, D., Heinzelmann-Schwarz, V. A., Schlaak, M., Kvasnicka, H.-M., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0198 · Cited by 203
van der Lee, M. M. C., Groothuis, P. G., Ubink, R., van der Vleuten, M. A. J., van Achterberg, T. A., Loosveld, E. M., Damming, D., Jacobs, D. C. H., Rouwette, M., Egging, D. F., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0881-t · Cited by 201
The development of pyrrolobenzodiazepines as antitumour agents
Hartley, J. A. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.573477 · Cited by 175
Younes, A., Kim, S., Romaguera, J., Copeland, A., Farial, S. D. C., Kwak, L. W., Fayad, L., Hagemeister, F., Fanale, M., Neelapu, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4403 · Cited by 170
Self-citationOroudjev, E., Lopus, M., Wilson, L., Audette, C., Provenzano, C., Erickson, H., Kovtun, Y., Chari, R., & Jordan, M. A. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0645 · Cited by 164
Siegel, P. M., Rose, A. A. N., Annis, M. G., & Maric (2013) · OncoTargets and Therapy · doi:10.2147/ott.s44906 · Cited by 152
Issell, B. F., & Crooke, S. T. (1978) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(78)80014-0 · Cited by 152
Galsky, M. D., Eisenberger, M., Moore-Cooper, S., Kelly, W. K., Slovin, S. F., DeLaCruz, A., Lee, Y., Webb, I. J., & Scher, H. I. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0532 · Cited by 145
Kaufman, J. L., Niesvizky, R., Stadtmauer, E. A., Chanan-Khan, A. A., Siegel, D. S. D., Horne, H. B., Wegener, W. A., & Goldenberg, D. M. (2013) · British Journal of Haematology · doi:10.1111/bjh.12565 · Cited by 128
Modeling the efficacy of trastuzumab-DM1, an antibody drug conjugate, in mice
Jumbe, N. L., Xin, Y., Leipold, D. D., Crocker, L., Dugger, D., Mai, E., Sliwkowski, M. X., Fielder, P. J., & Tibbitts, J. (2010) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-010-9156-2 · Cited by 119 · cited 1×
“emtansine induced tumor regression at dose levels at or above 3 mg/kg, but more potent efficacy was observed at 15 mg/kg [13,14].”
BackgroundMacrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Oflazoglu, E., Stone, I. J., Gordon, K. A., Grewal, I. S., van Rooijen, N., Law, C., & Gerber, H. (2007) · Blood · doi:10.1182/blood-2007-06-097014 · Cited by 117
Efficacy of Selected Natural Products as Therapeutic Agents against Cancer
Banerjee, S., Wang, Z., Mohammad, M., Sarkar, F. H., & Mohammad, R. M. (2008) · Journal of Natural Products · doi:10.1021/np0705716 · Cited by 107
High Turnover of Tissue Factor Enables Efficient Intracellular Delivery of Antibody–Drug Conjugates
de Goeij, B. E. C. G., Satijn, D. P. E., Freitag, C. M., Wubbolts, R., Bleeker, W. K., Khasanov, A. B., Zhu, T., Chen, G., Miao, D., van Berkel, P. H. C., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0798 · Cited by 99
Pollack, V. A., Álvarez, E., Tse, K. F., Torgov, M. Y., Xie, S., Shenoy, S. G., MacDougall, J. R., Arrol, S., Zhong, H., Gerwien, R. W., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0490-z · Cited by 82
Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia
Stasi, R. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.4.527 · Cited by 54
Anti-CD30 Antibodies for Hodgkin Lymphoma
Foyil, K. V., & Bartlett, N. L. (2010) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-010-0053-y · Cited by 49
Cantuzumab mertansine in a three-times a week schedule: a phase I and pharmacokinetic study
Rodon, J. A., Garrison, M. A., Hammond, L. A., Bono, J. S. D., Smith, L. S., Forero, L., Hao, D., Takimoto, C. H. M., Lambert, J. M., Pandite, L. N., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0672-8 · Cited by 37
Self-citationGörögh, T., Béress, L., Quabius, E. S., Ambrosch, P., & Hoffmann, M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-12 · Cited by 31
Kelly, K. R., Chanan-Khan, A. A., Somlo, G., Heffner, L. T., Siegel, D. S. D., Zimmerman, T. M., Jagannath, S., Munshi, N. C., Lonial, S., Roy, V., et al. (2013) · Blood · doi:10.1182/blood.v122.21.758.758 · Cited by 30
Thompson, J. A., Motzer, R. J., Molina, A. M., Choueiri, T. K., Heath, E. I., Kollmannsberger, C., Redman, B. G., Sangha, R. S., Ernst, D. S., Пили, Р., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2503 · Cited by 25
Gan, H. K., Papadopoulos, K. P., Fichtel, L., Lassman, A. B., Merrell, R. T., van den Bent, M. J., Kumthekar, P., Scott, A. M., Pedersen, M., Gomez, E. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2016 · Cited by 21
Petrylak, D. P., Kantoff, P. W., Mega, A. E., Vogelzang, N. J., Stephenson, J., Fleming, M. T., Stambler, N., Petrini, M., Huang, K., & Israel, R. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.6_suppl.119 · Cited by 19
Goff, L. W., Papadopoulos, K. P., Posey, J. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e15625 · Cited by 18
Mega, A. E., Petrylak, D. P., Kantoff, P. W., Stephenson, J., Vogelzang, N. J., Dreicer, R., Shore, N. D., Stambler, N., Carpenito, J., D’Ambrosio, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.4662 · Cited by 18
Moore, K. N., Ponte, J., LoRusso, P. M., Birrer, M. J., Bauer, T. M., Borghaei, H., O’Malley, D. M., Ruiz-Soto, R., Lutz, R., & Malik, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5571 · Cited by 16
Liu, J. F., Moore, K. N., Birrer, M. J., Berlin, S. T., Matulonis, U. A., Infante, J. R., Xi, J., Kahn, R., Wang, Y., Wood, K., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-290 · Cited by 12
Zhang, J., Gallery, M. A., Wyant, T. L., Stringer, B., Manfredi, M. G., Danaee, H., & Veiby, P. O. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-13-pr12 · Cited by 9
Yardley, D. A., Melisko, M., Forero, A., Daniel, B. R., Montero, A. J., Guthrie, T. H., Canfield, V. A., Oakman, C. A., Chew, H. K., Ferrario, C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.tps1110 · Cited by 9
Cited by
Batlle, E., & Clevers, H. (2017) · Nature Medicine · doi:10.1038/nm.4409 · Cited by 2,769
Unlocking the potential of antibody–drug conjugates for cancer therapy
Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,150
High-Resolution Native Mass Spectrometry
Tamara, S., den Boer, M. A., & Heck, A. J. R. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00212 · Cited by 511
Antibody-Drug Conjugate-Based Therapeutics: State of the Science
Birrer, M. J., Moore, K. N., Betella, I., & Bates, R. C. (2019) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djz035 · Cited by 439
Mechanisms of ADC Toxicity and Strategies to Increase ADC Tolerability
Nguyen, T. D., Bordeau, B. M., & Balthasar, J. P. (2023) · Cancers · doi:10.3390/cancers15030713 · Cited by 441
Metadata
- Authors
- de Goeij, B. E., & Lambert, J. M.
- Venue
- Current Opinion in Immunology
- Publisher
- Elsevier BV
- Published
- 2016-06
- Volume
- 40
- Pages
- 14-23
- ISSN
- 0952-7915 (ISSN-L)
- OpenAlex
- W2295236527
- Cited by
- 256
- References
- 57
- FWCI
- 8.25
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.